LGD4033 10mg Product Description
LGD-4033 is a selective androgen receptor modulator (SARMS), and a novel non-steroidal oral SARM that binds to AR with high affinity (Ki of ~1 nM) and selectivity. It’s in a class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.
LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds to the androgen receptor with high affinity and selectivity. It demonstrates anabolic activity in muscles, anti-resorptive and anabolic activity in bones and a robust selectivity for muscle and bone versus prostate and sebaceous glands. LGD-4033 has recently completed a Phase I Multiple Ascending Dose study in healthy volunteers. This randomized, double-blind, placebo-controlled Phase I study established the safety and tolerability up to doses of 22 mg per day.
Ligandrol is an orally active nonsteroidal SARM developed by Ligand Pharmaceuticals that has completed Phase I clinical trials which involved multiple ascending doses in healthy volunteers.
According to the National Institute of Health’s U.S. National Library of Medicine, in Phase I clinical trials “Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.” These clinical trials showed that humans could safely tolerate up to 22mg/day of this compound for 14 consecutive days; this compound
contributed to increases in lean body mass, decreases in fat mass, increases in strength, as well as an increases in senses of well-being.
Ligandrol also appears to decrease bone turnover rate, which appeals to those with osteoporosis. Based on these findings, it appears that LGD4033 is an excellent SARM for bulking, cutting, recomposition, or strength-gain phases.
LGD4033 10mg Product Application
LGD is still fairly new (3-5 years), but the results have been very similar in studies and logs. LGD-4033 has undergone several recent studies and trials to find the best and safest way to use it. From these trials, the results have shown increases in lean body mass and decreases in body fat. There is also a significant increase in strength, well being, as well as healing possibilities.
LGD has shown the most ability of any SARM to put on size that could be considered a bulk. This will, of course, be dependent upon the diet used. Users that have experienced more than 10lb. increases, and have had a significant increase in calorie intake. The possibility of this type of size is present with LGD use. A recommend dosage for this type of goal would be 5-10 mg day for 8 weeks.
LGD seems to shine with this method. Many have seen an increase in lean body mass and a decrease in body fat. LGD seems to work the best with this method. Ran in conjunction with other SARMS, like cardarine (GW-501516), will only increase the likelihood of a stronger recomp. Recommended doses for recomping would be 5-8 mg a day for 8 weeks.
LGD can be used to cut as well. It will shine more-so if ran in conjunction with SARMS S-4 and Cardarine (GW-501516). This would be similar to a SARMS triple stack that is normally ran with Ostarine, except there is a possibility of more size being put on while cutting. A good dose for this method would be 3-5 mg a day for 8 weeks
Reviews
There are no reviews yet.